What condition does Xtandi primarily treat?

Xtandi, known generically as enzalutamide, is primarily used in the treatment of prostate cancer, specifically castration-resistant prostate cancer. This medication functions as an androgen receptor inhibitor, which means it blocks the effects of male hormones that can promote the growth of prostate cancer cells.

The approach Xtandi takes is critical in managing prostate cancer, particularly for patients who no longer respond to traditional hormone therapy. By targeting the androgen receptors, Xtandi can slow the progression of the disease, improve survival rates, and enhance the quality of life for patients diagnosed with this condition.

In contrast, the other options listed pertain to completely different medical concerns. Multiple myeloma is a type of blood cancer affecting plasma cells; anemia is a condition characterized by a deficiency of red blood cells or hemoglobin; and Crohn's disease is an inflammatory bowel disease. None of these conditions are treated with Xtandi, reinforcing the focus of the drug on prostate cancer.